Format
Items per page
Sort by

Send to:

Choose Destination

Links from PubMed

Items: 1 to 20 of 108

1.

Bridging with the Low molecular weight heparin certoparin in patients requiring temporary discontinuation of oral anticoagulation - the non-interventional, retrospective REMEMBER study.

Eisele R, Melzer N, Englert C, Bramlage P, Spannagl M.

Thromb Res. 2012 Nov;130(5):788-92. doi: 10.1016/j.thromres.2011.12.039. Epub 2012 Jan 26.

PMID:
22281069
2.

AFFECT: a prospective, open-label, multicenter trial to evaluate the feasibility and safety of a short-term treatment with subcutaneous certoparin in patients with persistent non-valvular atrial fibrillation.

Tebbe U, Oeckinghaus R, Appel KF, Heuer H, Haake H, Eggers E, Seidel K, Adams J, Harenberg J.

Clin Res Cardiol. 2008 Jun;97(6):389-96. doi: 10.1007/s00392-008-0644-y. Epub 2008 Mar 5.

PMID:
18322636
3.

The duration of anticoagulation bridging therapy in clinical practice may significantly exceed that observed in clinical trials.

Deerhake JP, Merz JC, Cooper JV, Eagle KA, Fay WP.

J Thromb Thrombolysis. 2007 Apr;23(2):107-13.

PMID:
17221327
4.

Prospective, non-interventional study on the real-world use of certoparin in daily practice--the PROMEMBER study.

Spannagl M, Melzer N, Bramlage P, Englert C, Eisele R.

Clin Appl Thromb Hemost. 2013 Jan-Feb;19(1):86-91. doi: 10.1177/1076029612449899. Epub 2012 Jun 12.

PMID:
22696592
5.
6.
7.

Patients requiring interruption of long-term oral anticoagulant therapy: the use of fixed sub-therapeutic doses of low-molecular-weight heparin.

Malato A, Saccullo G, Lo Coco L, Caramazza D, Abbene I, Pizzo G, Casuccio A, Siragusa S.

J Thromb Haemost. 2010 Jan;8(1):107-13. doi: 10.1111/j.1538-7836.2009.03649.x. Epub 2009 Oct 11.

PMID:
19817996
8.

Low-molecular-weight-heparins as periprocedural anticoagulation for patients on long-term warfarin therapy: a standardized bridging therapy protocol.

Jaffer AK, Ahmed M, Brotman DJ, Bragg L, Seshadri N, Qadeer MA, Klein A.

J Thromb Thrombolysis. 2005 Aug;20(1):11-6.

PMID:
16133889
9.

Clinical outcomes with unfractionated heparin or low-molecular-weight heparin as bridging therapy in patients on long-term oral anticoagulants: the REGIMEN registry.

Spyropoulos AC, Turpie AG, Dunn AS, Spandorfer J, Douketis J, Jacobson A, Frost FJ; REGIMEN Investigators.

J Thromb Haemost. 2006 Jun;4(6):1246-52.

PMID:
16706967
10.

Standardized low-molecular-weight heparin bridging regimen in outpatients on oral anticoagulants undergoing invasive procedure or surgery: an inception cohort management study.

Pengo V, Cucchini U, Denas G, Erba N, Guazzaloca G, La Rosa L, De Micheli V, Testa S, Frontoni R, Prisco D, Nante G, Iliceto S; Italian Federation of Centers for the Diagnosis of Thrombosis and Management of Antithrombotic Therapies (FCSA).

Circulation. 2009 Jun 9;119(22):2920-7. doi: 10.1161/CIRCULATIONAHA.108.823211. Epub 2009 May 26.

11.

Treatment of venous thromboembolism: adherence to guidelines and impact of physician knowledge, attitudes, and beliefs.

Caprini JA, Tapson VF, Hyers TM, Waldo AL, Wittkowsky AK, Friedman R, Colgan KJ, Shillington AC; NABOR Steering Committee.

J Vasc Surg. 2005 Oct;42(4):726-33.

13.
14.

The HAS-BLED score predicts bleedings during bridging of chronic oral anticoagulation. Results from the national multicentre BNK Online bRiDging REgistRy (BORDER).

Omran H, Bauersachs R, Rübenacker S, Goss F, Hammerstingl C.

Thromb Haemost. 2012 Jul;108(1):65-73. doi: 10.1160/TH11-12-0827. Epub 2012 Apr 26.

PMID:
22534746
15.

Periprocedural bridging therapy in patients receiving chronic oral anticoagulation therapy.

Spyropoulos AC, Bauersachs RM, Omran H, Cohen M.

Curr Med Res Opin. 2006 Jun;22(6):1109-22. Review.

PMID:
16846544
16.

Safety of ablation for atrial fibrillation with therapeutic INR: comparison with transition to low-molecular-weight heparin.

Saad EB, Costa IP, Costa RE, Inácio LA Jr, Slater C, Camiletti A, Moura Neto DG, Maldonado P, Camanho LE, Polanczky CA.

Arq Bras Cardiol. 2011 Oct;97(4):289-96. Epub 2011 Aug 19. English, Portuguese.

17.

Bridging with enoxaparin using a half-therapeutic dose regimen: safety and efficacy.

Klamroth R, Gottstein S, Essers E, Landgraf H.

Vasa. 2010 Aug;39(3):243-8. doi: 10.1024/0301-1526/a000036.

PMID:
20737383
18.

Low-molecular-weight heparin (LMWH) in the treatment of thrombosis.

Holzheimer RG.

Eur J Med Res. 2004 Apr 30;9(4):225-39. Review.

PMID:
15210403
19.

Bridging of oral anticoagulation with low-molecular-weight heparin: experience in 373 patients with renal insufficiency undergoing invasive procedures.

Hammerstingl C, Omran H; Bonn Registry of Alternative Anticoagulation to Prevent Vascular Events.

Thromb Haemost. 2009 Jun;101(6):1085-90.

PMID:
19492151
20.

Antifactor Xa activity in critically ill patients receiving antithrombotic prophylaxis with standard dosages of certoparin: a prospective, clinical study.

Jochberger S, Mayr V, Luckner G, Fries DR, Mayr AJ, Friesenecker BE, Lorenz I, Hasibeder WR, Ulmer H, Schobersberger W, Dünser MW.

Crit Care. 2005 Oct 5;9(5):R541-8. Epub 2005 Aug 9.

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk